Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;642(8067):411-420.
doi: 10.1038/s41586-025-08813-6. Epub 2025 Apr 2.

Psilocybin's lasting action requires pyramidal cell types and 5-HT2A receptors

Affiliations

Psilocybin's lasting action requires pyramidal cell types and 5-HT2A receptors

Ling-Xiao Shao et al. Nature. 2025 Jun.

Erratum in

Abstract

Psilocybin is a serotonergic psychedelic with therapeutic potential for treating mental illnesses1-4. At the cellular level, psychedelics induce structural neural plasticity5,6, exemplified by the drug-evoked growth and remodelling of dendritic spines in cortical pyramidal cells7-9. A key question is how these cellular modifications map onto cell-type-specific circuits to produce the psychedelics' behavioural actions10. Here we use in vivo optical imaging, chemogenetic perturbation and cell-type-specific electrophysiology to investigate the impact of psilocybin on the two main types of pyramidal cells in the mouse medial frontal cortex. We find that a single dose of psilocybin increases the density of dendritic spines in both the subcortical-projecting, pyramidal tract (PT) and intratelencephalic (IT) cell types. Behaviourally, silencing the PT neurons eliminates psilocybin's ability to ameliorate stress-related phenotypes, whereas silencing IT neurons has no detectable effect. In PT neurons only, psilocybin boosts synaptic calcium transients and elevates firing rates acutely after administration. Targeted knockout of 5-HT2A receptors abolishes psilocybin's effects on stress-related behaviour and structural plasticity. Collectively, these results identify that a pyramidal cell type and the 5-HT2A receptor in the medial frontal cortex have essential roles in psilocybin's long-term drug action.

PubMed Disclaimer

Conflict of interest statement

Competing interests: A.C.K. has been a scientific advisor or consultant for Boehringer Ingelheim, Empyrean Neuroscience, Freedom Biosciences and Xylo Bio. A.C.K. has received research support from Intra-Cellular Therapies. The other authors declare no competing interests.

Update of

References

    1. Goodwin GM et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med 387, 1637–1648 (2022). 10.1056/NEJMoa2206443 - DOI - PubMed
    1. Davis AK et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry 78, 481–489 (2021). 10.1001/jamapsychiatry.2020.3285 - DOI - PMC - PubMed
    1. Carhart-Harris R et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med 384, 1402–1411 (2021). 10.1056/NEJMoa2032994 - DOI - PubMed
    1. Bogenschutz MP et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry 79, 953–962 (2022). 10.1001/jamapsychiatry.2022.2096 - DOI - PMC - PubMed
    1. Ly C et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep 23, 3170–3182 (2018). 10.1016/j.celrep.2018.05.022 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources